Working… Menu

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03316586
Recruitment Status : Active, not recruiting
First Posted : October 20, 2017
Last Update Posted : February 2, 2021
Bristol-Myers Squibb
Information provided by (Responsible Party):
Sara Tolaney, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : May 31, 2025